Smith Group Asset Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Smith Group Asset Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-10,459	Closed	-$164K	–	426
2015 Q1	$164K	Sell	10,459 -76,180	-88%	-$1.18M	0.01%	280
2014 Q4	$1.32M	Buy	86,639 +1,080	+1%	+$13.1K	0.05%	166
2014 Q3	$923K	Buy	85,559 +369	+0.4%	+$4.82K	0.03%	180
2014 Q2	$1.3M	Buy	+85,190	New	+$1.23M	0.05%	172

Other funds holding SGMO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Smith Group Asset Management's SGMO Position: Q2 2015 in Review

Smith Group Asset Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2015, closing a stake of 10,459 shares — an estimated $164K sold.

Smith Group Asset Management first reported a position in SGMO in Q2 2014 and held it in 4 quarters. The position peaked at $1.32M in Q4 2014. 156 funds tracked by Wall St. Rank hold SGMO as of Q2 2015.

Smith Group Asset Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2015 after selling out during the quarter.
Smith Group Asset Management sold 10,459 SANGAMO THERAPEUTICS INC shares in Q2 2015, an estimated $164K.
Smith Group Asset Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2014 and held it in 4 quarters.
Smith Group Asset Management's SANGAMO THERAPEUTICS INC position peaked at $1.32M in Q4 2014.
156 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2015.

Based on Smith Group Asset Management's 13F filing for Q2 2015, filed 29 Jul 2015.